Metraipolis › archive › dc_f457e18bbc9b

Real-World Outcomes of First-Line Pertuzumab, Trastuzumab, and Taxane in HER2-Positive Metastatic Breast Cancer in Costa Rica: A Multicenter Retrospective Study — Europe PMC PMID:41808700

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41808700
DOI
10.7759/cureus.104856
License (as archived)
solo-consultazione
Archived
2026-11-05T00:38:51.207Z
SHA-256 of the archived text
60ef8da368e0e842dea12dda9a3a3cab7c4a62f37f880e80a10ff2af964c467a
Stable URL of this page
https://metraipolis.com/documento/dc_f457e18bbc9b

How to cite

Real-World Outcomes of First-Line Pertuzumab, Trastuzumab, and Taxane in HER2-Positive Metastatic Breast Cancer in Costa Rica: A Multicenter Retrospective Study — Europe PMC PMID:41808700 — Europe PMC (en), https://europepmc.org/article/MED/41808700 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f457e18bbc9b (Metraipolis archive dc_f457e18bbc9b, sha256 60ef8da368e0e842dea12dda9a3a3cab7c4a62f37f880e80a10ff2af964c467a)
BibTeX
@misc{dcf457e18bbc9b,
  title = {Real-World Outcomes of First-Line Pertuzumab, Trastuzumab, and Taxane in HER2-Positive Metastatic Breast Cancer in Costa Rica: A Multicenter Retrospective Study — Europe PMC PMID:41808700},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41808700},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f457e18bbc9b; sha256 60ef8da368e0e842dea12dda9a3a3cab7c4a62f37f880e80a10ff2af964c467a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41808700. Agents can read the archived copy with the MCP tool read_document.